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Our previous phase II study of cisplatin and gemcitabine in malignant mesothelioma showed a 47.6% (95% CI 26.2–69.0%)
response rate with symptom improvement in responding patients. Here we conﬁrm these ﬁndings in a multicentre setting, and
assess the effect of this treatment on quality of life and pulmonary function. Fifty-three patients with pleural malignant
mesothelioma received cisplatin 100 mg m
72 i.v. day 1 and gemcitabine 1000 mg m
72 i.v. days 1, 8, and 15 of a 28 day cycle
for a maximum of six cycles. Quality of life and pulmonary function were assessed at each cycle. The best response achieved
in 52 assessable patients was: partial response, 17 (33%, 95% CI 20–46%); stable disease, 31 (60%); and progressive disease,
four (8%). The median time to disease progression was 6.4 months, median survival from start of treatment 11.2 months, and
median survival from diagnosis 17.3 months. Vital capacity and global quality of life remained stable in all patients and
improved signiﬁcantly in responding patients. Major toxicities were haematological, limiting the mean relative dose intensity of
gemcitabine to 75%. This schedule of cisplatin and gemcitabine is active in malignant mesothelioma in a multicentre setting.
Investigation of alternative scheduling is needed to decrease haematological toxicity and increase the relative dose intensity of
gemcitabine whilst maintaining response rate and quality of life.
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Malignant mesothelioma is an aggressive incurable tumour that is
increasing in incidence in a number of countries (de Klerk et al,
1989; Peto et al, 1995). The median survival from diagnosis ranges
from 6 to 18 months (Rusch et al, 1995) and conventional treat-
ments have not improved this poor prognosis (Ong and
Vogelzang, 1996; Sterman et al, 1999). We have previously reported
a single institution phase II study of the use of cisplatin and gemcita-
bine in the treatment of pleural malignant mesothelioma. Ten out
of 21 patients (47.6%) achieved a partial response of their disease
(95% CI 26.2–69.0%) (Byrne et al, 1999). The median duration of
response was 5.8 months, progression free survival 5.8 months, and
median survival from start of treatment 9.4 months. The median
survival of patients from the date of diagnosis was 12.9 months.
Although formal quality of life assessments were not performed,
nine of the 10 responding patients had signiﬁcant improvement
in symptoms. Serial measurements of vital capacity were performed
on three of the responders, all showed a signiﬁcant increase during
the period of remission.
Following these encouraging results, we designed this multicen-
tre phase II study to examine the objective response rate and
survival of patients treated with the same dose and schedule of
cisplatin and gemcitabine in a multicentre setting. We also
measured quality of life and lung function to assess the clinical
beneﬁt of this palliative therapy.
PATIENTS AND METHODS
Eligibility criteria
Patients were accrued from six tertiary referral centres across
Australia. Eligible patients had a histologically or cytologically
conﬁrmed diagnosis of malignant pleural mesothelioma, age 475
years, ECOG performance status of 0–2, and a life expectancy of
more than 12 weeks. All patients had had either bidimensionally
measurable disease of 1.561.5 cm or greater, or unidimensionally
measurable disease consisting of pleural tumour of at least 1.5 cm
in thickness on thoracic CT scan. All had adequate haematological
parameters (total leucocyte count 43.0610
9 l
71; granulocyte
count 41.5610
9 l
71; platelet count 4100610
9 l
71; and haemo-
globin 410 g dl
71), adequate renal function (serum creatinine
5120 mmol l
71), and adequate hepatic function (total bilirubin
51.56upper limit of normal (ULN); alanine transaminase and
alkaline phosphatase 536ULN). Patients were ineligible if they
had had prior systemic chemotherapy for malignant mesothelioma,
radiotherapy to all measurable lesions, or a second primary malig-
nancy diagnosed within the past 10 years. Pregnant or lactating
women and patients with other serious medical disorders incompa-
tible with the study were also considered ineligible. Patients found
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not considered eligible for assessment of response. The protocol
was approved by the Committee for Human Rights of the Univer-
sity of Western Australia and the Sir Charles Gairdner Hospital
Clinical Drug Trials Committee, and also by the ethics committee
of each participating centre. Written informed consent was
obtained from each patient prior to study entry.
Treatment administration
All patients received cisplatin 100 mg m
72 intravenously over 1 h
on day 1 and gemcitabine 1000 mg m
72 over 30 min on days 1, 8,
and 15. On day 1, cisplatin was administered before gemcitabine.
Cisplatin was administered as an inpatient or outpatient according
to individual institutional practice but with a minimum of 3 l
intravenous hydration and magnesium supplementation. Prophy-
lactic antiemetic therapy with 5-hydroxytryptamine (5-HT3)
antagonists and dexamethasone was given intravenously on days
1, 8 and 15. Oral 5-HT3 antagonists and/or dexamethasone and/
or phenothiazine antiemetics orally or by suppository were contin-
ued for 3–5 days following cisplatin.
Cycles were repeated every 28 days. In the absence of disease
progression or unacceptable toxicity, patients were scheduled to
receive six cycles. A complete blood count and differential, serum
electrolytes, creatinine, bilirubin, ALT, alkaline phosphatase, albu-
min and total protein were performed on day 1 of each cycle.
On days 8 and 15, a full blood count and differential were
performed.
Dose adjustments
No dose escalations were permitted. On days 1, 8 and 15, the dose
of gemcitabine was adjusted according to the level of myelosup-
pression on that day. The gemcitabine dose was reduced to 50%
if the total leucocyte count was 2.0–2.9610
9 l
71, and omitted
(or delayed 1 week for day 1) at 52.0610
9 l
71. Gemcitabine
was reduced to 50% if the platelet count was 50–74610
9 l
71,
and omitted at 550610
9 l
71. Cisplatin was not adjusted for
myelosuppression. Treatment with growth factors (G-CSF) was
not allowed unless there was evidence of severe myelosuppression.
On days 1, 8, or 15, the cisplatin and gemcitabine doses were
modiﬁed according to renal function. The gemcitabine dose was
reduced to 75% and cisplatin dose to 50% if the serum creatinine
was 120–150 mmol l
71. Serum creatinine 4150 mmol l
71 led to
treatment delay. Grade 3 mucosal or skin toxicity resulted in a dose
reduction of 50% for gemcitabine until the toxicity abated. No
dose adjustments were allowed for nausea and vomiting.
Tumour assessment
Clinical history and examination, chest X-ray, vital capacity (FVC)
and FEV1 were required prior to study entry and on day 1 of each
cycle. A CT scan of the thorax and abdomen was performed prior
to study entry, and a further CT scan of the thorax was performed
prior to day 1 of the second, fourth, and sixth cycles and again at
the end of the sixth cycle. Thereafter, CT scans were performed at
8 weekly intervals until disease progression. QOL was assessed
using the EORTC QLQ-C30 questionnaire (Aaronson et al, 1993)
supplemented by the lung cancer module QLQ-LC13, prior to
study entry and on day 1 of cycles 2, 4, and 6, and 8 weekly there-
after until disease progression.
Tumour measurements were performed on transverse cuts on
thoracic CT scans at three separate anatomically reproducible levels
on the study entry CT scan and at the same levels on subsequent
scans. Where possible, bidimensional lesions were measured. If
there were no bidimensionally measurable lesions, unidimensional
measurements of pleural tumour thickness were performed. Bi-
dimensionally measurable lesions were measured using the longest
dimension and the length perpendicular to the longest measure-
ment. For unidimensionally measurable lesions, thickness of
pleural tumour was measured at two separate sites on each level
and the measurements summated to produce a total measurement.
Palpable masses were measured clinically on day 1 of each cycle as
for bidimensionally measurable lesions. A pleural effusion was not
considered a measurable lesion.
Tumour response
Tumour response was deﬁned as: (1) complete response: disap-
pearance of all known disease, determined by two observations
not less than 4 weeks apart, (2) partial response: a 50% or greater
decrease in the sum of the products of perpendicular diameters of
bidimensionally measured lesions on two occasions not less than 4
weeks apart, or greater than or equal to a 30% decrease in the sum
of linear tumour measurements on two observations not less than
4 weeks apart, (3) no change: a decrease in bidimensional tumour
area of less than 50% or an increase of less than 25%; or a decrease
in the sum of unidimensional measurements of less than 30% or
an increase of less than 25%; provided no new lesions have
appeared, (4) progressive disease: a 25% or greater increase in
the size of the tumour being measured (unidimensional or bi-
dimensional) or the appearance of new lesions.
Where response at sites measured bidimensionally differed from
that at sites measured unidimensionally the overall patient response
was assessed by the audit group. The sites with dominant tumour
bulk were favoured.
Assessment of endpoints
Patients who died of mesothelioma in whom there was no change
or a response were regarded as having disease progression at the
time of death. Time to disease progression was measured from
the date of ﬁrst chemotherapy dose to the ﬁrst date of progression
or death. Duration of response was measured from the ﬁrst date of
partial response to the ﬁrst date of progression or death. Time to
treatment failure was measured from day 1 of the ﬁrst cycle of
chemotherapy until the ﬁrst of either disease progression, death
in the absence of disease progression, or premature discontinuation
of the protocol therapy. Survival was deﬁned as the time from day
1 of the ﬁrst cycle of chemotherapy until death.
Survival from the date of ﬁrst diagnosis was also recorded.
Treatment toxicity was recorded according to the National Cancer
Institute (NCI) Common Toxicity Criteria, version 2.0.
Treatment discontinuation
Treatment was discontinued on disease progression, following
unacceptable toxicity in the opinion of the investigator, or on
patient refusal to continue.
Pathology and radiology review
Representative histological and cytological slides from each patient
were centrally reviewed by one pathologist at Sir Charles Gairdner
Hospital and a panel of immunohistochemical markers was
performed on each case to ensure uniformity of diagnosis and
histological subtyping. Initial CT scans of all patients were reviewed
by a radiologist at Sir Charles Gairdner Hospital to ensure unifor-
mity of staging according to UICC TNM criteria (Hermanek and
Sobin, 1992). All CT scans were reviewed and measured for
response centrally at Sir Charles Gairdner Hospital, and CT scans
of patients considered responders were further audited by a panel
of clinicians. If assessment of response or time of progression
differed between the peripheral institution and central review at
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panel of clinicians who had ﬁnal arbitration over response cate-
gory.
Statistical considerations
The study was designed to use the one-sample multiple testing
procedure of Fleming (1982). The aim was to recruit a minimum
of 15 patients initially, with a maximum of 35 patients in stages of
15, 10, and 10 patients. Analysis of the interim results was
performed after each stage when patients became fully assessable.
This allowed for early termination of the study if it became evident
that the true rate of response (complete plus partial) was less than
20% or greater than 40%. Statistical analysis was conducted using
the SPSS for Windows statistical package. Survival data were
analysed with Kaplan–Meier survival curves. Quality of life data
and lung function tests were not normally distributed and were
analysed using the non-parametric Mann–Whitney U test. Differ-
ences were considered signiﬁcant when the P value was less than
0.05.
RESULTS
Patient characteristics
Fifty-ﬁve patients were entered in the study, of whom 53 were
eligible. The characteristics of the 53 eligible patients are listed in
Table 1. One patient with peritoneal mesothelioma without pleural
disease was deemed ineligible, and another patient was found to
have adenocarcinoma on pathology review and at subsequent
autopsy. The 53 eligible patients were included in the analysis.
As all patients were required to have measurable disease, the
majority of patients had advanced disease at study entry with 46
(87%) having UICC TNM stage III or IV disease. Forty-eight
patients (91%) had Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1. The majority of patients (79%) had
epithelioid tumours. Three patients (6%) were diagnosed with
malignant mesothelioma on cytology alone. One patient was
judged to have non-measurable disease following central radiology
review, as it was difﬁcult to distinguish pleural ﬂuid from solid
lesions. This patient is not included in assessment of response,
and is included as a ‘non-responder’ in analysis of QOL and
pulmonary function tests. Nine (17%) patients had measurable
subcutaneous lesions and 25 (48%) patients had at least one
intrathoracic bidimensionally measurable lesion that was used in
assessment of response.
Treatment delivered
Nineteen patients completed the scheduled six cycles of treatment.
The median number of cycles administered per patient was four.
The relative dose intensity of cisplatin delivered was high (median,
100%; mean, 97%), however this was lower for gemcitabine
(median, 72%; mean, 75%). Out of 227 planned day 1 treatments,
28 were delivered with a dose reduction. Out of 223 planned day 8
treatments, 39 were dose-reduced and 13 omitted. On day 15, 36
out of 219 planned treatments were dose-reduced and 90 omitted.
The mean relative dose intensity delivered to responders (71%) was
lower than that for patients with stable disease (78%) or progres-
sive disease (73%) as best response. This reﬂects cumulative
myelotoxicity as responders received more cycles of treatment than
non-responders (mean 4.9 cycles vs 4.1 cycles).
Response to treatment
No patient had a complete response. Seventeen patients (33%) had
a partial response, and 31 patients (60%) had stable disease as their
best response to treatment. Four patients (7%) had progressive
disease, with no period of stabilisation. The overall response rate
was 33% (95% CI 20–46%). The median duration of response
was 5.4 months (range, 2.8–17.3 months) for those 17 patients
achieving a partial response. The median time to progression was
6.4 months (Figure 1). The median survival from start of treatment
was 11.2 months (Figure 2), and the median survival from diagno-
sis of malignant mesothelioma was 17.3 months for all patients.
Responding patients had a median survival from start of treatment
of 12.2 months, as compared with 9.1 months for non-responders.
This difference was not signiﬁcant. A partial response was observed
in 13 out of 42 patients with epithelioid tumours (31%), in three
out of seven patients with sarcomatoid tumours (43%), and in one
of two patients with biphasic tumours. Out of ﬁve patients with
ECOG performance status 2 at study entry, three had progressive
disease as their best response, and only one attained a partial
response.
Toxicity
The major toxicities recorded were haematological, with 49% of
patients experiencing grade 3 or 4 thrombocytopenia and 56%
grade 3 or 4 neutropenia during treatment (Table 2). Infection
however was uncommon, with only two patients (4%) developing
febrile neutropenia during the course of treatment. There were no
treatment-related deaths. Grade 1 and 2 anaemia was common,
experienced by 74% of patients, but only 7% had grade 3 anaemia.
Twenty-one patients required blood transfusion in 31 cycles, and
13 patients required platelet transfusion in 17 cycles. Nausea and
vomiting were the major symptomatic toxicities, with 75 and
60% of patients respectively describing grade 1 or 2 nausea and
vomiting, and 20 and 17% describing grade 3 nausea and vomiting.
Thirteen percent of patients had grade 3 neurotoxicity, predomi-
nantly ototoxicity.
Pulmonary function tests and quality of life
There was no signiﬁcant change in FVC from baseline in the whole
group (Figure 3). There was a signiﬁcant difference between
responding (PR) and non-responding (SD and PD) patients
(P=0.002) with an improvement in FVC in patients attaining
partial response. FVC did not differ signiﬁcantly from baseline in
non-responding patients.
Among responding patients there was a signiﬁcant improve-
ment in the EORTC-QLQ-C30 global QOL scale (P=0.006)
compared to non-responding patients over six cycles of
chemotherapy (Figure 4). This difference did not persist in ques-
tionnaires completed following the cessation of chemotherapy. In
the patient group as a whole, there was no signiﬁcant change from
baseline in global QOL, nor in the physical, role, emotional,
cognitive or social function scales during chemotherapy. There
was no signiﬁcant difference in the cognitive, role or social func-
tion scales between responders and non-responders. Responders
showed improved physical function scores (P=0.01) as compared
with non-responders, and non-responders showed improved
emotional function scores (P=0.04) as compared with responders.
In the EORTC-QLQ-C30 symptom scales, symptoms that
improved signiﬁcantly were appetite (at cycle six), diarrhoea,
nausea and vomiting, and insomnia. There was no signiﬁcant
change in scores for pain, dyspnoea, constipation or ﬁnancial
problems. Fatigue was the only symptom scale which worsened
from baseline in the group as a whole (P50.005). There were
no differences between responders and non-responders for any
of the QLQ-C30 symptom scales. Only small numbers of patients
reported pulmonary symptoms other than dyspnoea, cough and
chest pain. As assessed by the QLQ-LC13 in the group as a whole,
cough and chest pain scores decreased signiﬁcantly from baseline
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increased signiﬁcantly at cycle six.
DISCUSSION
This multicentre study conﬁrms the efﬁcacy of this 28-day regimen
of cisplatin and gemcitabine in the treatment of pleural malignant
mesothelioma, with an overall response rate of 33% accompanied
by improved global QOL and FVC among responding patients.
This suggests that the regimen has greater efﬁcacy in this disease
than most other reported single agents or combinations, as no
drugs have consistently induced a response greater than 20%
(Ong and Vogelzang 1996).
Neither cisplatin with a response rate of 13–14% (Mintzer et al,
1985; Zidar et al, 1988), nor gemcitabine (response rate 0–31%)
(Bischoff et al, 1998; van Meerbeeck et al, 1999; Kindler et al,
2001) have shown great promise as single agents in the treatment
of this disease. The additive or synergistic interaction of the two
drugs documented in vitro (Peters et al, 1995) and in animal
models (Peters et al, 1996) may underlie the useful clinical effects
demonstrated in this study. Other combinations involving cisplatin
(Thodtmann et al, 1999), or oxaliplatin (Fizazi et al, 2000) with
other antimetabolites have shown promise in single studies and
conﬁrmatory studies with functional and QOL end points are
awaited.
There is only one reported randomised phase III trial of
chemotherapy in this disease. In a subset analysis which excluded
patients with poor prognosis there was a survival advantage for
patients receiving onconase over doxorubicin (11.3 vs 9.1 months)
(Vogelzang et al, 2000).
The median survival of 11.2 months from start of treatment
we observed is encouraging in a setting of advanced, measurable
disease. When ﬁrst seen, a number of patients had non-measur-
able disease and were not eligible for treatment. They became
eligible weeks to months later as disease progressed. The inclu-
sion requirement of measurable disease together with a life
expectancy of more than 12 weeks may have selected for a group
of patients with more indolent disease, which may have inﬂu-
enced survival from start of treatment and the unusually long
median survival from diagnosis of 17.3 months. Survival is gener-
ally reported as 8–12 months. The question of whether this
regimen improves survival can only be answered with a rando-
mised controlled trial.
Patients with an ECOG performance status (PS) of 2 at study
entry comprised the majority (75%) of those who had progressive
disease as best response. Three out of ﬁve patients with PS 2
showed early progression, whilst one of 47 patients with PS 0–1
showed early progression. This is similar to the reported experience
in non-small cell lung cancer, and patients with PS 2 are now
excluded from many trials in this disease (Frasci et al, 2000; Schil-
ler et al, 2000). Patients with pleural malignant mesothelioma who
have a poor performance status may similarly derive less beneﬁt
from chemotherapy.
Our previous study suggested that patients with epithelioid
tumours may have been more likely to respond to this combina-
tion. Sixty-nine per cent of patients with epithelioid tumours
responded as compared with only 14% with biphasic tumours.
Although the numbers of patients with biphasic and sarcomatoid
tumours in this multi-center study were too small to perform a
sub-group analysis, the response rate of 31% amongst those with
epithelioid tumours and 43% amongst those with sarcomatoid
tumours does not reinforce our previous observation.
Delivery of the full, scheduled dose intensity of gemcitabine was
hampered by haematological toxicity, with dose reduction or omis-
sion commonly required at day 15, particularly in patients
receiving more cycles of treatment. Dose omission was most
commonly due to thrombocytopenia, while neutropenia was a
frequent cause of dose reduction. Despite the common occurrence
of severe neutropenia, there were only two reported incidents of
febrile neutropenia. There were no deaths due to infection.
When our original pilot study of cisplatin and gemcitabine was
initiated in 1995, this 28 day cycle with cisplatin given day 1 was
the most well described schedule of delivery of this drug combina-
tion. This trial aimed to conﬁrm the efﬁcacy of the regimen in a
multicentre setting, and thus we did not alter our established sche-
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Table 1 Patient demographics and baseline characteristics
Number Per cent
Sex
Male 45 85
Female 8 15
Age, years
Median 63
Range 47–76
UICC TNM stage
I6 1 1
II 0 0
III 33 62
IV 13 25
Unable to stage 1 2
Histopathology
Epithelioid 42 79
Sarcomatoid 7 13
Biphasic 2 4
Unknown 2 4
ECOG performance status
01 7 3 2
13 1 5 9
25 9
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Figure 1 Time to progression (all patients) from start of treatment.
P
e
r
c
e
n
t
 
s
u
r
v
i
v
i
n
g
100
90
80
70
60
50
40
30
20
10
0
Median 11.2 months
0 6 12 18 24 30 36 42
Months from start of treatment
Figure 2 Overall survival from start of treatment.
Cisplatin and gemcitabine in mesothelioma
AK Nowak et al
494
British Journal of Cancer (2002) 87(5), 491–496 ã 2002 Cancer Research UKdule in this second trial. Alternative schedules have been described
for a variety of tumours. Some investigators have given cisplatin on
days 2 or 15 of a 28 day cycle (Abratt et al, 1997; Crino et al,
1997), or split the cisplatin dose for days 1, 8 and 15 (Shepherd
et al, 1997, 2000). Others have shortened the cycle to 21 days,
administering cisplatin on day 1 (Rosell et al, 1998) or days 1
and 8 (Nagourney et al, 2000). Comparisons of toxicity between
trials suffer from differing patient groups and deﬁnitions of haema-
tological toxicity. There is, however, some consensus that schedules
using cisplatin 100 mg m
72 on day 1 of a 28 day cycle are less able
to deliver the full dose of gemcitabine due to frequent dose omis-
sions and reductions for haematological toxicity on day 15 (Abratt
et al, 1998). One small randomised trial tends to conﬁrm the better
tolerance of day 15 vs day 2 cisplatin delivery in a 28 day cycle
(Ricci et al, 2000). A 21 day schedule may allow the delivery of
a greater relative dose intensity of gemcitabine. It may also be
useful to split the dose of cisplatin in an effort to decrease nausea
and vomiting. However, we cannot assume that other schedules
will be equally efﬁcacious against malignant mesothelioma without
appropriate clinical trials. A different schedule of this combination
in malignant mesothelioma has been trialed by another group and
reported in abstract form: gemcitabine 1250 mg m
72 days 1 and 8
and cisplatin 80 mg m
72 day 1 were administered to 29 patients
on a 21 day cycle (van Haarst et al, 2000). Only four out of 22
evaluable patients (18%) had a partial response. WHO response
criteria were used to evaluate response in this study. These criteria
are difﬁcult to apply to malignant mesothelioma in view of the
unique growth pattern of tumour, as a ‘rind’ around the pleural
cavity with less prominent bidimensionally measurable lesions. In
contrast, our studies of this combination have included unidimen-
sional measurements and response criteria similar to the RECIST
criteria (Therasse et al, 2000) in addition to bidimensional
measurements when possible. Thus the response rates in these
studies may not be directly comparable.
We are aware of quality of life analysis in only one other study
of chemotherapy in this disease. Steele et al (2000) treated 29
patients with weekly single agent vinorelbine 30 mg m
72.
Twenty-four per cent achieved a partial response of their disease
with a median survival from start of treatment of 10.6 months,
and from diagnosis of 13.8 months. Quality of life data were
collected 6-weekly using the Rotterdam Symptom checklist. After
the ﬁrst 6 weeks of treatment, 48% showed an improvement in
lung related symptoms, 41% an improvement in general physical
symptoms, and 76% an improvement in psychological symptoms.
Activity levels worsened in 52% of patients. These ﬁgures were
similar in patients continuing to further cycles of chemotherapy,
and improvements were recorded in patients with stable disease
as well as responding patients. It is not possible to directly compare
the results of QOL data between these two trials due to the differ-
ences in measurement tools used, however both trials indicate that
some patients obtain symptomatic and QOL beneﬁt which may
occur in the absence of objective response.
Given that FVC was signiﬁcantly improved in responders, and
remained unchanged from baseline in non-responders it was
surprising to ﬁnd no improvement in dyspnoea as assessed by
the QLQ-C30 and the QLQ-LC13 instruments. We can hypothesise
either that improvement in FVC may not translate to an improve-
ment in dyspnoea, or was too small to demonstrate an
improvement. This seems unlikely, given that the mean increase
in FVC for responders at cycle 5 was over 30%. Alternatively,
the three questions that comprise the ‘dyspnoea’ domain in the
QLQ-LC13 may not be a sensitive reﬂection of changes in
dyspnoea in patients with malignant mesothelioma. The high inci-
dence of grade 2 and 3 anaemia, which was cumulative with
increasing cycles of chemotherapy, may also contribute to a lack
of perceived improvement in dyspnoea, as may treatment-related
fatigue. It is also clear that the QLQ-LC13 Lung Cancer module
may not be as well adapted for the symptom proﬁle of malignant
mesothelioma as it is for lung cancer. Symptoms of haemoptysis,
arm pain, and dysphagia were rarely reported in our patients.
However, troublesome chest wall masses and anorexia are relatively
common symptoms in malignant mesothelioma which were not
well assessed by this questionnaire. In the absence of an untreated
control group it is difﬁcult to assess whether this palliative
chemotherapy regimen is beneﬁcial to QOL. Whilst we would
expect considerable deterioration over 6 months in the natural
history of this disease, most domains do not appear to have dete-
riorated in the patient group as a whole over this period of
chemotherapy.
We have conﬁrmed in a multicentre setting that cisplatin and
gemcitabine in this dose and schedule produces objective responses
in a third of treated patients. Response to treatment is accompa-
nied by improved global QOL and improved respiratory
function. This regimen provides a satisfactory palliative treatment
for some patients with advanced pleural mesothelioma.
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Table 2 Treatment toxicity. Worst grade (% of patients)
1234
Thrombocytopenia 32 15 17 32
Neutropenia 11 9 32 24
Leucopenia 13 40 30 6
Anaemia 19 55 7 0
Nausea 32 43 20 0
Vomiting 31 29 17 0
Neurotoxicity 25 8 13 0
Infection 7 4 4 0
Diarrhoea 11 7 2 0
Stomatitis 13 4 0 0
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Figure 3 PercentagechangeinFVCfrombaselineoversixcyclesofchemo-
therapy. There was a signiﬁcant difference between responding and non-
responding patients during chemotherapy (P=0.002).
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Figure 4 Global health status over six cycles of chemotherapy. Respond-
ing patients had a signiﬁcantly improved global quality of life during treat-
ment as compared with non-responders (P=0.008).
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